蛋白质组学的研究进展

作者:刘嘉;李冬;王徐;代大年; 刊名:现代医药卫生 上传者:姚庆六

【摘要】1994年,澳大利亚科学家首次提出了蛋白质组的概念。蛋白质组是指所有基因表达的所有蛋白质及其存在方式,是由单个基因组、细胞、组织或个体表达的完整蛋白质组分~([1])。蛋白质组学主要阐明生物体中所有蛋白质的表达和功能模式,分析细胞内动态变

全文阅读

2014,41( 3): 1-14. [ 7] STUPP R,BRADA M,BENT MJ,et al.High-grade glioma:ES-MO Clinical Practice Guidelines for diagnosis,treatment and fol-low-up[ J].Ann Oncology,2014,25(Suppl 3):93-101. [ 8] HEGI ME,DISERENS AC,GORLIA T, et al.MGMT gene silen-cing and benefit from temozolomide in glioblastoma[ J].N Engl J Med,2005,352( 1):997-1003. [ 9] MALMSTROM A,GRONBERG BH,MAROSI C,et al.Temozo-lomide versus standard 6-week radiotherapy versus hypofraction-ated radiotherapy in patients older than 60years with glioblasto- ma:the Nordic randomised, phase 3trial[ J].Lancet Oncol,2012, 13( 1):916-926. [ 10]WICK W,PLATTEN M,MEISNER C, et al.Temozolomide chemo-therapy alone versus radiotherapy alone for malignant astrocyto- ma in the elderly:the NOA-08randomised, phase 3trial[ J].Lan- cet Oncol,2012,13( 1):707-715. [ 11]TAAL W,OOSTERKAMP HM,WALENKAMP AM,et al.Sin- gle-agent bevacizumab or lomustine versus a combination of bev-acizumab plus lomustine in patients with recurrent glioblastoma ( BELOB trial): a randomised controlled phase 2trial[ J].Lancet Oncol,2014,15( 9):943-953. [ 12]STUPP R,WONG ET,KANNER AA,et al.NovoTTF-100Aversus physician′s choice chemotherapy in recurrent glioblasto-ma: a randomized phase Ⅲ trial of a novel treatment modality [ J].Eur J Cancer,2012,48(14):2192-2202. [ 13]HAN SJ,ROLSTON JD,MOLINARO AM,et al.PhaseⅡ trialof 7days on/7days off temozolmide for recurrent high-grade glio- ma[ J].Neuro Oncol,2014,16( 9):1255-1262. [ 14]廖加群,黄立敏,易敏,等.替莫唑胺剂量密度方案联合顺铂治疗 复发高级别胶质瘤效果观察[

参考文献

引证文献

问答

我要提问